Deciphera Pharmaceuticals, a member of ONO, is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines aimed at improving the lives of cancer patients. Utilizing its proprietary switch-control kinase inhibitor platform and extensive expertise in kinase biology, Deciphera has built a diverse pipeline of drug candidates, including the approved QINLOCK® for fourth-line GIST treatment. The company is recognized for its outstanding workplace culture, having been certified as a Great Place to Work in 2023 and ranking #25 on Fortune’s Best Places to Work Small and Midsized Biotech Companies. Headquartered in Waltham, Massachusetts, with a state-of-the-art research facility in Lawrence, Kansas, Deciphera is committed to fostering personal and professional growth among its employees.